Literature DB >> 17616749

The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation.

Ramanna Merla1, Yumei Ye, Yu Lin, Saraswathy Manickavasagam, Ming-He Huang, Regino J Perez-Polo, Barry F Uretsky, Yochai Birnbaum.   

Abstract

Statins activate phosphatidylinositol-3-kinase, which activates ecto-5'-nucleotidase and phosphorylates 3-phosphoinositide-dependent kinase-1 (PDK-1). Phosphorylated (P-)PDK-1 phosphorylates Akt, which phosphorylates endothelial nitric oxide synthase (eNOS). We asked if the blockade of adenosine receptors (A(1), A(2A), A(2B), or A(3) receptors) could attenuate the induction of Akt and eNOS by atorvastatin (ATV) and whether ERK1/2 is involved in the ATV regulation of Akt and eNOS. In protocol 1, mice received intraperitoneal ATV, theophylline (TH), ATV + TH, or vehicle. In protocol 2, mice received intraperitoneal injections of ATV, U0126 (an ERK1/2 inhibitor), ATV + U0126, or vehicle; 8 h later, hearts were assessed by immunoblot analysis. In protocol 3, mice received intraperitoneal ATV alone or with 8-sulfophenyltheophylline (SPT); 1, 3, and 6 h after injection, hearts were assessed by immunoblot analysis. In protocol 4, mice received intraperitoneal ATV alone or with SPT, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), 1,3,7-trimethyl-8-(3-chlorostyryl)xanthine (CSC), alloxazine, or MRS-1523; 3 h after injection, hearts were assessed by immunoblot analysis. ATV increased P-ERK, P-PDK-1, Ser(473) P-Akt, Thr(308) P-Akt, and P-eNOS levels. TH blocked ATV-induced increases in P-ERK, Ser(473) P-Akt, Thr(308) P-Akt, and P-eNOS levels without affecting the induction of P-PDK-1 by ATV. U0126 blocked the ATV induction of Ser(473) P-Akt and Thr(308) P-Akt while attenuating the induction of P-eNOS. A detectable increase in P-ERK, Ser(473) P-Akt and P-eNOS was seen 3 and 6 h after injection but not at 1 h. DPCPX, CSC, and alloxazine partially blocked the ATV induction of P-ERK, Ser(473) P-Akt, and P-eNOS. In conclusion, blockade of adenosine A(1), A(2A), and A(2B) receptors but not A(3) receptors inhibited the induction of Akt and eNOS by statins. Adenosine was required for ERK1/2 activation by statins, which resulted in Akt and eNOS phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616749     DOI: 10.1152/ajpheart.00416.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  21 in total

1.  Simvastatin induces a central hypotensive effect via Ras-mediated signalling to cause eNOS up-regulation.

Authors:  Wen-Han Cheng; Wen-Yu Ho; Chien-Feng Chang; Pei-Jung Lu; Pei-Wen Cheng; Tung-Chen Yeh; Ling-Zong Hong; Gwo-Ching Sun; Michael Hsiao; Ching-Jiunn Tseng
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

Review 2.  Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of nine randomized controlled trials.

Authors:  Yangchun Liu; Qiang Su; Lang Li
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

3.  Atorvastatin Promotes Cytotoxicity and Reduces Migration and Proliferation of Human A172 Glioma Cells.

Authors:  Karen A Oliveira; Tharine Dal-Cim; Flávia G Lopes; Fabiana K Ludka; Cláudia B Nedel; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2017-02-08       Impact factor: 5.590

4.  Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.

Authors:  Nassrene Y Elmadhun; Antonio D Lassaletta; Louis M Chu; Yuhong Liu; Jun Feng; Frank W Sellke
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-17       Impact factor: 5.209

5.  Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress.

Authors:  X Y Tian; W T Wong; A Xu; Z Y Chen; Y Lu; L M Liu; V W Lee; C W Lau; X Yao; Y Huang
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

6.  Statin post-treatment provides protection against simulated ischemia in bovine pulmonary arterial endothelial cells.

Authors:  Xing Wu; Daowei Lin; Guofu Li; Zhiyi Zuo
Journal:  Eur J Pharmacol       Date:  2010-03-31       Impact factor: 4.432

Review 7.  Cardiac NO signalling in the metabolic syndrome.

Authors:  O Pechánová; Z V Varga; M Cebová; Z Giricz; P Pacher; P Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

8.  Pyruvate-fortified cardioplegia evokes myocardial erythropoietin signaling in swine undergoing cardiopulmonary bypass.

Authors:  Myoung-Gwi Ryou; Devin C Flaherty; Besim Hoxha; Jie Sun; Hunaid Gurji; Steven Rodriguez; Glenn Bell; Albert H Olivencia-Yurvati; Robert T Mallet
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-18       Impact factor: 4.733

Review 9.  Update on statin-mediated anti-inflammatory activities in atherosclerosis.

Authors:  Fabrizio Montecucco; François Mach
Journal:  Semin Immunopathol       Date:  2009-05-05       Impact factor: 9.623

10.  Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways.

Authors:  Fabrizio Montecucco; Maria Bertolotto; Luciano Ottonello; Alessandra Quercioli; François Mach; Franco Dallegri
Journal:  J Biomed Biotechnol       Date:  2009-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.